Congress pushes a ban that would erase hemp‑derived CBD while a Medicare pilot reimburses the same products.
Policy clash threatens patient access
The new law redefines hemp to include total THC, even THCA, and caps each container at 0.4 mg THC.
That limit makes it impossible for most CBD creams, gummies and tinctures to stay legal, despite the products themselves containing no detectable THC.
At the same time, a Medicare pilot covers CBD up to 3 mg THC per serving, creating a direct conflict between federal policy and patient care.
Nationwide use of CBD for health reasons
Pacific Legal Foundation research shows CBD use spans every region and demographic group, with millions turning to it for pain, anxiety, sleep disorders and other conditions.
Survey data indicates a majority of adults have tried CBD, many citing medical reasons and aiming to reduce reliance on prescription drugs.
Older Americans, including Medicare beneficiaries, represent a large share of consumers, underscoring the product’s mainstream health relevance.
State actions versus federal overreach
State legislatures have largely respected patient autonomy, allowing regulated hemp markets to flourish without waiting for federal approval.
Federal attempts to restrict hemp now risk stalling that momentum and limiting alternatives for millions of patients.
Time running out to fix the problem
Congress denied amendments in June that would have softened the hemp restrictions, and the White House urged updates to the statutory definition to preserve access.
If legislation cannot be passed before the Dec. 11 deadline, an extension to pause the ban is the only realistic path to avoid a bureaucratic morass that would sink a promising medical innovation.
Washington must align its Medicare access with its hemp regulations, or it will block the very care it seeks to support.
Originally published in USA Today on September 8 2026.
